Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Trial evidence across STAMPEDE and ENZARAD suggests systemic treatment intensification primarily aids localized prostate cancer patients with very high-risk disease, such as conventional N1 status. Broad high-risk classifications remain too heterogeneous to justify intensified AR pathway inhibition for everyone.

Related Insights

The negative ANSA-RAD trial, when contrasted with the positive STAMPEDE trial, demonstrates that patient selection is paramount in adjuvant therapy. The difference in outcomes was driven by risk definition, not the drug. This reinforces that "negative" trials are clinically vital for defining which patient populations do not benefit, preventing widespread overtreatment.

The debate over the STAMPEDE and ENSA-RAD trials stems from a misunderstanding. They aren't contradictory but study different cohorts within the "high-risk" category. STAMPEDE focused on the highest-risk patients, while ENSA-RAD included a broader group. Combining their data could provide a more nuanced treatment approach.

The EMBARK trial showed that enzalutamide monotherapy was superior to standard ADT monotherapy for metastasis-free survival. This suggests potent AR antagonism may be a more effective strategy than simply depleting the testosterone ligand, challenging the long-held dogma of ADT being the fundamental building block for systemic prostate cancer therapy.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

Early neoadjuvant trials in the 1990s failed to show clinical benefit because they included many low-risk patients and used less potent hormonal therapies. The PROTEUS trial's success was built on learning from this history by strictly enrolling high-risk patients and using a powerful androgen receptor pathway inhibitor (ARPI).

Major trials in prostate (PEACE-2), bladder (Keynote B15), and kidney cancer (LITESPARK-022) showcase a common strategy: moving potent systemic therapies into earlier, curative-intent settings. This approach of using the best drugs sooner aims to improve long-term outcomes, though it also raises questions about toxicity and overtreatment.

Clinical trials combining potent ARPIs like abiraterone and enzalutamide have consistently failed. Once the androgen receptor pathway is maximally suppressed by one agent, adding another with a similar mechanism provides no further clinical advantage, much like hammering a nail that is already flush with the wood.

The standard of care for metastatic castration-sensitive prostate cancer has evolved. ADT plus an ARPI is now the baseline treatment for nearly every patient. Referring to it as 'intensification' is outdated and misrepresents its role as the new standard.

A VA study using real-world data confirms that androgen receptor pathway inhibitors (ARPIs) combined with ADT significantly improve survival in elderly (>75), frail, and high-comorbidity prostate cancer patients. This evidence directly addresses clinician hesitancy to treat these vulnerable populations with standard-of-care combination therapy.

The IMbark trial demonstrated that an ARPI (enzalutamide), either alone or with ADT, outperformed ADT monotherapy in high-risk patients. This pivotal finding raises the question of whether giving ADT alone in any setting, such as with radiation for localized disease, is now an outdated and inferior approach.